Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.
| Autor: | de Oliveira Almeida, Gustavo, Nienkötter, Thiago Faraco, Balieiro, Caroline Cristine Almeida, Pasqualotto, Eric, Cintra, Júlia Braga, Carvalho, Henrique Champs Porfírio, Silva, Ana Laura Soares, Kabariti, Júlia Camargo, Minucci, Bárbara Silvestre, Bertoli, Edmundo Damiani, Guida, Camila Mota |
|---|---|
| Předmět: |
MYOCARDIAL infarction risk factors
CARDIOVASCULAR disease prevention GLUCAGON-like peptide-1 agonists MEDICAL information storage & retrieval systems PLACEBOS VENOUS thrombosis CARDIOVASCULAR diseases risk factors HYPOGLYCEMIC agents META-analysis DESCRIPTIVE statistics SYSTEMATIC reviews MEDLINE ODDS ratio DIASTOLIC blood pressure MEDICAL databases ATRIAL fibrillation SYSTOLIC blood pressure ONLINE information services CONFIDENCE intervals STROKE OBESITY PHARMACODYNAMICS |
| Zdroj: | American Journal of Cardiovascular Drugs; Jul2024, Vol. 24 Issue 4, p509-521, 13p |
| Abstrakt: | Background: GLP-1 receptor agonists (GLP-1 RAs) have emerged as an effective therapeutic class for weight loss. However, the efficacy of these agents in reducing cardiovascular endpoints among patients living with obesity or overweight is unclear. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1 RAs versus placebo in patients with obesity or overweight. We searched PubMed, Cochrane, and Embase databases. A random-effects model was used to calculate risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CIs). Results: A total of 13 RCTs were included, with 30,512 patients. Compared with placebo, GLP-1 RAs reduced systolic blood pressure (MD − 4.76 mmHg; 95% CI − 6.03, − 3.50; p < 0.001; I2 = 100%) and diastolic blood pressure (MD − 1.41 mmHg; 95% CI − 2.64, − 0.17; p = 0.03; I2 = 100%). GLP-1 RA significantly reduced the occurrence of myocardial infarction (RR 0.72; 95% CI 0.61, 0.85; p < 0.001; I2 = 0%). There were no significant differences between groups in unstable angina (UA; RR 0.84; 95% CI 0.65, 1.07; p = 0.16; I2 = 0%), stroke (RR 0.91; 95% CI 0.74, 1.12; p = 0.38; I2 = 0%), atrial fibrillation (AF; RR 0.49; 95% CI 0.17, 1.43; p = 0.19; I2 = 22%), and deep vein thrombosis (RR 0.30; 95% CI 0.06, 1.40; p = 0.13; I2 = 0%). Conclusions: In patients living with obesity or overweight, GLP-1 RA reduced systolic and diastolic blood pressure and the occurrence of myocardial infarction, with a neutral effect on the occurrence of UA, stroke, AF, and deep vein thrombosis. Registration: PROSPERO identifier number CRD42023475226. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink